The global lung cancer diagnostic and screening market is estimated to be valued at US$ 3,515.9 million in 2028 and is expected to exhibit a CAGR of 7.8% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Lung cancer is a type of cancer that begins in the lungs and most often occurs in people who smoke. Lung cancer develops when normal lung cells change, or mutate, in a way that alters their natural growth and death cycle, resulting in unregulated cell division that produces too many cells. There are two main types of lung cancer, such as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Both are treated differently.
LIMITED TIME OFFER – Hurry Up!!!
Buy Now To Avail Flat 30% Off
Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/4434
Lung cancer is inherently more difficult to diagnose because an individual can neither see nor feel the lungs, so the main way it is diagnosed is when it causes symptoms such as a cough or pain. Some lung cancers can be found by screening or by looking at a sample of lung cells in the laboratory. The only recommended screening test for lung cancer is low-dose computed tomography (also called a low-dose CT scan, or LDCT). LDCT is the current “gold standard” tests to screen and diagnose for lung cancer.
Competitive Landscape:
Major players operating in the lung global cancer diagnostic and screening market are Janssen Pharmaceuticals, Inc., Sanofi, AstraZeneca, Agilent Technologies, Inc., Myriad Genetics Inc., Danaher, F. Hoffmann-La Roche Ltd, NanoString, NeoGenomics, QIAGEN, Illumina, Abbott, Thermo Fischer Scientific, and Quest Diagnostics Incorporated, among others.
Key Market Drivers:
Increasing prevalence of lung cancer across the world is expected to propel growth of the lung cancer diagnostic and screening market over the forecast period. For instance, according to the World Health Organization (WHO), more than 2.21 million people around the world diagnosed with lung cancer in 2020. Moreover, according to cnacer.net, an estimated 2.3 million people around the world will be diagnosed with lung cancer in 2021.
Get Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/4434
Furthermore, increasing research and development activities, increasing number of diagnostic centers, and emergence of new technologies or technological advancements are expected to augment the growth of the lung cancer diagnostic and screening market. For instance, in June 2020, Roche announced the CE-IVD launch of its automated digital pathology algorithm, the uPath PD-L1 (SP263) image analysis for NSCLC. The algorithm provides pathologists with automated assessments of scanned slide images that are objective and reproducible and have the potential to aid diagnosis and, ultimately, targeted treatment options for patients.
COVID-19 Impact Analysis:
The outbreak of COVID-19 has resulted in many elective procedures being put on hold, and this has led to a substantial decline in the cancer screening. The pandemic has had considerable impact on the delivery of oncology services worldwide. However, healthcare facilities around the world are providing cancer diagnostic and screening during the pandemic with many safety precautions to curb the spread of the novel coronavirus. In short, the pandemic has had a dual impact on the lung cancer diagnostic and screening market.
Key Takeaways:
- The lung cancer diagnostic and screening market is expected to exhibit a CAGR of 7.8 % during the forecast period due to the increasing number of product launches, collaborations, and partnership strategies adopted by market players. For instance, in June 2019, Roche launched its first in vitro diagnostic test to target ROS1 positive lung cancers, VENTANA ROS1 (SP384) Antibody.
- Among regions, North America, Europe, and Asia Pacific are expected to witness robust growth in the lung cancer diagnostic and screening market due to the increasing prevalence lung cancer, increasing number of product launches, increasing research and development activities, and emergence of new technologies in the region. For instance, according to the American Cancer Society, in 2021, there will be an estimated 235,760 new cases of lung cancer diagnosed and 131,880 cancer deaths in the United States. Moreover, in December 2020, UK launched public-private iDx-Lung consortium to improve early detection of lung cancers. The iDx-LUNG project aims to improve the efficiency of testing in people at high risk of cancer.
Reasons to Purchase This Report
• Current and future of Lung Cancer Diagnostic and Screening Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/4434
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Test Type
- Market Snippet, By Cancer Type
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Product Launches/Approvals
- Regulatory Scenario
- Epidemiology
- Porter’s Analysis
- PEST Analysis
- Acquisition and Collaboration Scenario
- Global Lung Cancer Diagnostic and Screening Market – Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Impact of COVID-19 on lung cancer diagnostic and screening market
- Government Initiative
- Global Lung Cancer Diagnostic and Screening Market, By Test Type, 2017 – 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Biomarker Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- EGFR Mutation Tests
- KRAS Mutation Tests
- ALK Tests
- HER2 Tests
- Others
- Imaging Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Computed Tomography (CT) scan
- Positron Emission Tomography (PET) scan
- Chest X- Ray
- Others
- Biopsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Needle Biopsy
- Bronchoscopy Biopsy
- Open Biopsy
- Others
- Introduction
- Global Lung Cancer Diagnostic and Screening Market, By Cancer Type, 2017 – 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Non-small cell lung cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Small Cell Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Lung Cancer Diagnostic and Screening Market, By End User, 2017 – 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospital Associated Labs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Independent Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Diagnostic Imaging Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Cancer Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Global Lung Cancer Diagnostic and Screening Market, By Region, 2017 – 2028, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2018 – 2028
- Regional Trends
- North America
- Market Size and Forecast, By Product Type, 2017 – 2028, (US$ Million)
- Market Size and Forecast, By Application, 2017 – 2028, (US$ Million)
- Market Size and Forecast, By End User, 2017 – 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Million)
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/lung-cancer-diagnostic-and-screening-market-3697
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837